Ugandan firm Quality Chemicals Industrial Limited (QCIL) plans to produce Duomune as a new anti-retroviral drug, that will be taken a single tablet, rather than in combination with others.
QCIL says the recommended dose of Duomune is one tablet, taken orally, once daily with food. It is designed for adults above the age of 18. QCIL Executive Director Emmanuel Katongole says production begins in May after QCIL has secured the National Drugs Authority approval.
Copyright © 2013 The Observer. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.
AllAfrica aggregates and indexes content from over 130 African news organizations, plus more than 200 other sources, who are responsible for their own reporting and views. Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica.
Comments Post a comment